Bina Therapeutics Publishes Preclinical Results of TRAABA24
TRAABA24 Preclinical Results Share This Article: Abstract Background: Pseudomyxoma peritonei (PMP) is a rare malignancy with limited treatment options. Mitomycin C (MMC) is a frontline chemotherapeutic used in hyperthermic intraperitoneal chemotherapy (HIPEC) due to its potent cytotoxicity via DNA cross-linking. However, its severe systemic toxicity restricts use to localized administration. TRAABA24, a lipid nanoparticle (LNP) […]
Protected: Computational Drug Discovery for Pseudomyxoma Peritonei
There is no excerpt because this is a protected post.
